verteporfin


Also found in: Wikipedia.

verteporfin

 [ver″tĕ-por´fin]
a photosensitizing agent that accumulates preferentially in neovasculature, including that in the choroid, such as occurs in age-related macular degeneration, ocular histoplasmosis, or pathologic myopia; the agent is then activated by light of a specific wavelength in the presence of oxygen, and causes local damage to the neovascular endothelium followed by vessel occlusion; it is administered intravenously prior to irradiation of the lesion with light from a compatible laser.

ver·te·por·fin

(vĕr-tē-pōr'fin),
Photosensitizer agent used in photodynamic therapy to treat choroidal neovascularization secondary to age related macular degeneration.

verteporfin

/ver·te·por·fin/ (ver″tĕ-por´fin) a photosensitizing agent that accumulates preferentially in neovasculature, including that in the choroid; used, together with appropriate laser irradiation of the lesion, in the treatment of neovascularization due to disciform macular degeneration, to presumed ocular histoplasmosis, or to pathologic myopia.

verteporfin

[ver′tĕ-por′fin]
a photosensitizing agent that accumulates preferentially in neovasculature, including that in the choroid, such as occurs in age-related macular degeneration, ocular histoplasmosis, or pathological myopia. The agent is then activated by light of a specific wavelength in the presence of oxygen and causes local damage to the neovascular endothelium followed by vessel occlusion. It is administered intravenously before irradiation of the lesion with light from a compatible laser.
References in periodicals archive ?
PDT involved intravenously injecting a photosensitising drug called Verteporfin into the patient's circulation, where it became concentrated in areas of neovascularisation within the macula.
Contract award notice: Pnsp 21/2017 dabrafenib, Nilotinib, Everolimus, Lapatinib, Pazopanib, Basiliximab, Mycophenolic acid, Verteporfin and octreotide.
In the period leading up to 2005, intravitreal injection (CPT 67028) of medications slowly became popular as treatment modality for age-related macular degeneration after the Food and Drug Administration approval of verteporfin.
This approval is based on the results of the Phase III RADIANCE study, which indicated that treatment with Lucentis provided superior visual acuity gains in people with mCNV compared to verteporfin photodynamic therapy.
Photodynamic therapy with verteporfin in the treatment of exudative idiopathic polypoidal choroidal vasculopathy.
The structural, [14] angiographic, [13] and biological effects [13] induced by verteporfin therapy may cause increased subretinal haemorrhage after treatment.
Verteporfin (Visudyne) was the first drug therapy approved by the FDA for treatment of wet AMD, but newer drugs have largely replaced its use.
Visudyne, or verteporfin photodynamic therapy, a combination of drug and diode laser treatment, was approved in 2000 and represented the first major advance over the commonly used laser photocoagulation that was associated with vision loss and deleterious effects on the retina.
Ladd B, Solomon S, Bressler N, Bressler S 2001 Photodynamic therapy with verteporfin for choroidal neovascularization in patients with diabetic retinopathy American Journal of Ophthalmology 132 (5) 659-667
One is PDT, which is a laser treatment that is administered in conjunction with verteporfin (Visudyne), a light-sensitizing drug injected intravenously to selectively close the vessels within the affected area.
In the smaller study, the control group also received a standard treatment--the drug verteporfin followed by laser light, which activates verteporfin.